Skip to main content
SP5007,691.76-0.69%DOW53,343.40-0.22%NASDAQ26,289.71-1.33%BTC$64,489.00+0.25%ETH$1,913.40+0.26%GOLD$4,397.30-0.53%OIL$84.77+0.84%
Smart Investors Daily
Sign InSign Up Free
AA

NASDAQ · AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

Healthcare · Biotechnology

$18.20

Up-$0.00 (+0.00%)

Updated Aug 19, 2026, 5:27 AM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.23B
P/E ratio
-12.12
Dividend yield
0.00%
52-week range
$16.36 – $48.45
Volume
6.88K
Avg. volume
3.2K

Price performance

AAPG price history

1M range · 20 trading sessions · Daily adjusted prices

AAPG closed at $18.20 after 20 trading sessions, down 4.72% for the selected period.

Last close
$18.20
Period change
-4.72%
Period low
$16.69
Period high
$19.33
Daily close
View OHLC price history
AAPG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 18, 2026$17.92$18.1991$17.40$18.19916.88K
Aug 17, 2026$18.30$18.4846$18.00$18.205.88K
Aug 13, 2026$19.17$19.19$18.985$19.002.98K
Aug 12, 2026$18.64$18.97$18.57$18.972.63K
Aug 11, 2026$18.87$18.9799$18.74$18.97993.28K
Aug 10, 2026$18.68$18.86$18.68$18.863.47K
Aug 7, 2026$18.49$18.985$18.31$18.9858.68K
Aug 6, 2026$17.13$17.13$16.7701$17.093.9K
Aug 5, 2026$17.00$17.00$16.7625$16.8554.62K
Aug 4, 2026$17.0994$17.0994$16.57$16.695.54K
Aug 3, 2026$17.55$17.55$16.75$16.80514.16K
Jul 31, 2026$17.60$17.60$17.2401$17.4254K
Jul 30, 2026$18.43$18.43$17.68$18.072.61K
Jul 29, 2026$18.10$18.31$18.10$18.314.29K
Jul 28, 2026$18.5499$18.5499$18.25$18.2854.67K
Jul 27, 2026$18.32$19.00$18.32$18.892.02K
Jul 24, 2026$17.97$18.6594$17.97$18.294.58K
Jul 23, 2026$19.12$19.3251$19.12$19.32511.32K
Jul 22, 2026$19.31$19.40$19.135$19.23511.6K
Jul 21, 2026$18.895$19.10$18.77$19.104.99K

Latest AAPG news

The latest Smart Investors Daily articles mentioning AAPG.

Stock researchCompany · Overview

AAPG research

Overview

Company profile and research snapshot.

Company profile

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$48.00
Implied upside
—
Analysts
13
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 5, 2026

CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

In a release issued under the same headline earlier today by Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855),please note that in the first paragraph of the release, the time should be 7:00 am Eastern Daylight Time (EDT) on August 19, 2026 / 7:00 pm Hong Kong Time (HKT) and not 9 am EDT and 9 pm HKT as previously stated.The corrected release follows: ROCKVILLE, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma

Yahoo · Aug 5, 2026

Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

ROCKVILLE, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that it will release its six months 2026 unaudited interim results and provide business updates at 9:00 am Eastern Daylight Time (EDT) on August

Yahoo · Aug 2, 2026

Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer

Appointments put dedicated leadership behind two separate priorities: building Ascentage Pharma’s own commercial organization in the United States, and expanding its global business development programROCKVILLE, Md., Aug. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By